Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in
patients with chronic myelogenous leukemia in chronic phase with age more than 70, diagnosis
of cml is being performed within 1 year. Quality of life will be carefully assessed.